Cargo carrying pivotal-ready CD22 CAR with $200M A round

Based on promising clinical data from co-founder Crystal Mackall, Cargo has raised $243 million to get its CD22 CAR T cell over the finish line for large B cell lymphoma patients who relapse after treatment with CD19 CARs. Behind the lead program is a platform that packs multiple genetic payloads into engineered cells, which the company thinks will facilitate additional strategies to overcome therapeutic resistance.

Operationalized by founding investor Samsara Biocapital, Cargo Therapeutics Inc. unveiled a $200 million series A round Wednesday led by Third Rock Ventures, RTW and Perceptive Xontogeny Venture Fund on the strength of the lead asset’s Phase I data.  ...